Page 49 - BH-2-4

Brain & Heart Transforming transthyretin cardiac amyloidosis

Conflict of interest doi: 10.1161/CIRCRESAHA.121.318187

The authors declare that they have no known competing 7. Takashio S, Morioka M, Ishii M, et al. Clinical characteristics,
interests. outcome, and therapeutic effect of tafamidis in wild-type
transthyretin amyloid cardiomyopathy. ESC Heart Fail.
Author contributions 2023;10(4):2319-2329.
doi: 10.1002/ehf2.14380
Conceptualization: Heet N. Desai
Data curation: Sarthak H. Dhruv 8. Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac
Methodology: Heet N. Desai, Riti Sanghvi, Sarthak H. amyloidosis. Cardiovasc Res. 2022;118(18):3517-3535.
Dhruv doi: 10.1093/cvr/cvac119
Writing–original draft: Heet N. Desai 9. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS.
Writing–review & editing: Heet N. Desai, Riti Sanghvi Transthyretin amyloid cardiomyopathy: JACC state-of-the-
Ethics approval and consent to participate art review. J Am Coll Cardiol. 2019;73(22):2872-2891.
doi: 10.1016/j.jacc.2019.04.003
Not applicable.
10. Wang J, Chen H, Tang Z, et al. Tafamidis treatment in
Consent for publication patients with transthyretin amyloid cardiomyopathy: A
systematic review and meta-analysis. EClinicalMedicine.
Not applicable. 2023;63:102172.

Availability of data doi: 10.1016/j.eclinm.2023.102172
Data are available from the corresponding author upon 11. Elliott P, Drachman BM, Gottlieb SS, et al. Long-term
survival with tafamidis in patients with transthyretin amyloid
reasonable request.
cardiomyopathy. Circ Heart Fail. 2022;15(1):e008193.
References doi: 10.1161/CIRCHEARTFAILURE.120.008193

1. Gościniak P, Baron T, Milczarek S, Kostkiewicz M, 12. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis
Machaliński B. Updates for the diagnosis and management of Treatment for patients with transthyretin amyloid
cardiac amyloidosis. Adv Clin Exp Med. 2022;31(2):175-185. cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016.
doi: 10.17219/acem/142252 doi: 10.1056/NEJMoa1805689
2. Raval M, Siddiq S, Sharma K, et al. A review of recent 13. Elliott P, Gundapaneni B, Sultan MB, Ines M, Garcia-Pavia P.
advances in the diagnosis of cardiac amyloidosis, treatment Improved long-term survival with tafamidis treatment
of its cardiac complications, and disease-modifying in patients with transthyretin amyloid cardiomyopathy
therapies. F1000Research. 2023;12:192. and severe heart failure symptoms. Eur J Heart Fail.
2023;25:2060-2064.
doi: 10.12688/f1000research.130285.1
doi: 10.1002/ejhf.2974
3. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac
amyloidosis: Evolving diagnosis and management: 14. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020
A scientific statement from the American heart association. statement: An updated guideline for reporting systematic
Circulation. 2020;142(1):E7-E22. reviews. BMJ. 2021;372:n71.
doi: 10.1161/CIR.0000000000000792 doi: 10.1136/bmj.n71
4. Damy T, Garcia-Pavia P, Hanna M, et al. Efficacy and 15. Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale
safety of tafamidis doses in the tafamidis in transthyretin for the quality assessment of narrative review articles. Res
cardiomyopathy clinical trial (ATTR-ACT) and long-term Integr Peer Rev. 2019;4(1):5.
extension study. Eur J Heart Fail. 2021l;23(2):277-285.
doi: 10.1186/s41073-019-0064-8
doi: 10.1002/ejhf.2027
16. Halpern SH. Appendix: Jadad scale for reporting randomized
5. Nuvolone M, Girelli M, Merlini G. Oral Therapy for the controlled trials. In: Evidence‐based Obstetric Anesthesia.
treatment of transthyretin-related amyloid cardiomyopathy. United States: Wiley; 2005. p. 237-238.
Int J Mol Sci. 2022;23(24):16145.
doi: 10.1002/9780470988343.app1.
doi: 10.3390/ijms232416145
17. Checklist for Case Reports Critical Appraisal tools for use
6. Griffin JM, Rosenblum H, Maurer MS. Pathophysiology in JBI Systematic Reviews. Available from: https://www.
and therapeutic approaches to cardiac amyloidosis. Circ Res. coursehero.com/file/215346388/checklist-for-case [Last
2021;128(10):1554-1575. accessed on 2024 Jul 15].

Volume 2 Issue 4 (2024) 9 doi: 10.36922/bh.4250